{"result": "(\"entity\"<|>URGENTES<|>EVENT<|>Urgent care visit for bilateral lumbar pain with ureteral irradiation and urinary symptoms without fever on 17/5/97)\n##\n(\"entity\"<|>HÍGADO<|>GEO<|>The liver where four nodules were found during urgent ultrasound examination)\n##\n(\"entity\"<|>PÁNCREAS<|>GEO<|>The pancreas where a 3 cm nodule was found during urgent ultrasound examination)\n##\n(\"entity\"<|>MEDICINA INTERNA<|>ORGANIZATION<|>Internal Medicine department where the patient was admitted for further study)\n##\n(\"entity\"<|>CIPROFLOXACINO<|>ORGANIZATION<|>Antibiotic used to resolve urinary tract infection)\n##\n(\"entity\"<|>TAC<|>EVENT<|>CT scan performed to assess pancreatic irregularities and biliary dilation)\n##\n(\"entity\"<|>LAPAROTOMÍA EXPLORADORA<|>EVENT<|>Exploratory laparotomy performed on 25/3/98 to investigate pancreatic and hepatic neoplasia)\n##\n(\"entity\"<|>CARCINOMA INDIFERENCIADO METASTÁSICO DE HÍGADO<|>GEO<|>Undifferentiated metastatic liver carcinoma of probable endocrine origin diagnosed post-surgery)\n##\n(\"entity\"<|>DTCI<|>ORGANIZATION<|>Dacarbazine treatment initiated on 2/6/98 for cancer therapy)\n##\n(\"entity\"<|>ENDOCINOLOGÍA Y NUTRICIÓN<|>ORGANIZATION<|>Endocrinology and Nutrition department consulted for significant weight loss)\n##\n(\"entity\"<|>ANALÍTICA<|>EVENT<|>Blood analysis performed to monitor liver function and overall health)\n##\n(\"entity\"<|>GAMMAGRAFÍA CON OCTREÓTIDO<|>EVENT<|>Octreotide scan requested to evaluate pancreatic uptake)\n##\n(\"entity\"<|>DUODENOPANCREATECTOMÍA TOTAL<|>EVENT<|>Total duodenopancreatectomy performed on 05/02/1999)\n##\n(\"entity\"<|>ESPLENECTOMÍA<|>EVENT<|>Splenectomy performed during the total duodenopancreatectomy)\n##\n(\"entity\"<|>GASTRECTOMÍA PARCIAL<|>EVENT<|>Partial gastrectomy performed during the total duodenopancreatectomy)\n##\n(\"entity\"<|>ANASTOMOSIS HEPATICOYEYUNAL<|>EVENT<|>Hepaticojejunostomy performed during the surgical procedure)\n##\n(\"entity\"<|>ANASTOMOSIS GASTROYEYUNAL<|>EVENT<|>Gastrojejunostomy performed during the surgical procedure)\n##\n(\"relationship\"<|>URGENTES<|>MEDICINA INTERNA<|>The patient was admitted to the Internal Medicine department after the urgent care visit<|>7)\n##\n(\"relationship\"<|>HÍGADO<|>TAC<|>CT scan was performed to assess the condition of the liver<|>6)\n##\n(\"relationship\"<|>PÁNCREAS<|>TAC<|>CT scan was performed to assess the condition of the pancreas<|>6)\n##\n(\"relationship\"<|>MEDICINA INTERNA<|>CIPROFLOXACINO<|>Ciprofloxacin was prescribed by the Internal Medicine department to treat the urinary tract infection<|>8)\n##\n(\"relationship\"<|>TAC<|>LAPAROTOMÍA EXPLORADORA<|>Exploratory laparotomy was performed following the CT scan results<|>7)\n##\n(\"relationship\"<|>LAPAROTOMÍA EXPLORADORA<|>CARCINOMA INDIFERENCIADO METASTÁSICO DE HÍGADO<|>The exploratory laparotomy revealed undifferentiated metastatic liver carcinoma<|>9)\n##\n(\"relationship\"<|>DTCI<|>ANALÍTICA<|>Blood analysis was conducted to monitor the effects of Dacarbazine treatment<|>6)\n##\n(\"relationship\"<|>ENDOCINOLOGÍA Y NUTRICIÓN<|>ANALÍTICA<|>Blood analysis was performed following the consultation with Endocrinology and Nutrition<|>5)\n##\n(\"relationship\"<|>GAMMAGRAFÍA CON OCTREÓTIDO<|>LAPAROTOMÍA EXPLORADORA<|>The Octreotide scan was requested to evaluate the condition before the exploratory laparotomy<|>6)\n##\n(\"relationship\"<|>DUODENOPANCREATECTOMÍA TOTAL<|>CARCINOMA INDIFERENCIADO METASTÁSICO DE HÍGADO<|>The total duodenopancreatectomy was performed due to the diagnosis of undifferentiated metastatic liver carcinoma<|>9)\n##\n(\"relationship\"<|>DUODENOPANCREATECTOMÍA TOTAL<|>ESPLENECTOMÍA<|>Splenectomy was part of the total duodenopancreatectomy procedure<|>8)\n##\n(\"relationship\"<|>DUODENOPANCREATECTOMÍA TOTAL<|>GASTRECTOMÍA PARCIAL<|>Partial gastrectomy was performed during the total duodenopancreatectomy<|>8)\n##\n(\"relationship\"<|>DUODENOPANCREATECTOMÍA TOTAL<|>ANASTOMOSIS HEPATICOYEYUNAL<|>Hepaticojejunostomy was performed as part of the total duodenopancreatectomy<|>8)\n##\n(\"relationship\"<|>DUODENOPANCREATECTOMÍA TOTAL<|>ANASTOMOSIS GASTROYEYUNAL<|>Gastrojejunostomy was performed as part of the total duodenopancreatectomy<|>8)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: que el 17/5/97 acude a Urgencias por dolor lumbar bilateral con irradiación ureteral y clínica miccional sin fiebre.\n\nEcografía urgente: imágenes hipoecoicas en hígado (4 nódulos) y páncreas (1 nódulo de 3 cm). Ingresa en Medicina Interna para estudio:\n- Urografía normal e ITU que se resuelve con Ciprofloxacino.\n---\n• TAC T-A: imagen hipodensa e irregularidad en proceso uncinado pancreático, mínimas hipodensidades en convexidad diafragmática hepática, aumento de tamaño de bazo y vena esplénica.\n\n• Marcadores tumorales Ca 19.9, CEA y alfafetoproteína (negativos).\n\n• Punción: frotis hemático sin malignidad citológica aparente.\n\n**Marzo 98**: nuevo ingreso por dolor en HCD, ictericia y coluria.\n\nTAC: dilatación de vías biliares intra y extrahepáticas, litiasis vesicular, lobulación pancreática con dilatación de Wirsung y pequeños nódulos peripancreáticos.\n\n**25/3/98**: LAPAROTOMÍA EXPLORADORA: neoplasia en istmo, proceso uncinado y cabeza de páncreas + múltiples nódulos hepáticos. Sólo biopsia.\n\nAP: CARCINOMA INDIFERENCIADO METASTÁSICO DE HÍGADO DE PROBABLE ORIGEN ENDOCRINO.\n\nInmunohistoquímica:\n- Citoqueratina +\n- Cromogranina -\n- Sinaptofisina +\n- EMA +\n- Enolasa neuroespecífica +\n\nConsulta de oncología: se remite para valoración terapéutica.\n\nEXPORACIÓN. FÍSICA: ECOG 2/3, ictericia y hepatomegalia 3 td.\n\nANALÍTICA: Hb 10,8 normocítica normocrómica. GOT 170, GPT 360, GGT 1034, Bil tot 7, ALP 1244, Alb 2,8 resto normal.\n\n**2/6/98**: inicia DTIC (Dacarbazina) d1-5 + 5FU d 1-5 cada 3 semanas al 50% dosis.\n\nToxicidad: Mucositis oral y genital G2 (sólo el 1º ciclo). Se aumenta dosis al 75% en el 3er ciclo y se llega a dosis plena en el 5º.\n\nConsulta de Endocrinología y Nutrición: se remite para valoración tras pérdida significativa de peso.\n\nEXPLORACIÓN FÍSICA: talla 180,5 cm, peso 70,5 kg, BMI 21,7.\n\nPeso habitual 82 kg (BMI 25,2), BMI 23 74 kg, % pérdida de peso 14%.\n\nSe hicieron recomendaciones dietéticas y se asociaron suplementos orales con una fórmula específica completa, hipercalórica, hiperproteica, baja en grasas, con EPA, DHA y antioxidantes, con un 16% de MCTs y fibra soluble en más de un 90%. Se recomendaron 2 envases al día (560 kcal y 29 gramos de proteínas)¹,².\n\nConsulta de Endocrinología y Nutrición (revisión): toma correctamente la suplementación.\n\nConsulta de Oncología Médica (valoración de respuesta). Valoración tras 6 ciclos: respuesta clínica completa + respuesta bioquímica casi completa (Bil tot 1, GOT 52, GPT 69).\n---\nRespuesta radiológica parcial TAC diciembre 98: discreto engrosamiento en cabeza de páncreas y metástasis hepática única de 7-8 mm.\n\nSe solicita Gammagrafía con Octreótido que resulta ser positiva con captación en la cabeza de páncreas.\n\nSe plantea nueva laparotomía exploradora y valorar tratamiento quirúrgico radical.\n\nEXPLORACIÓN FÍSICA: talla 180,5 cm, peso 71,5 kg, BMI 22,0.\n\nANALÍTICA: Hb 12,3 GOT 78, GPT 81, GGT 137, Alb 3,2 resto normal.\n\nTratamiento Quirúrgico.\n\n05/02/1999: DUODENOPANCREATECTOMÍA TOTAL + ESPLENECTOMÍA + GASTRECTOMÍA PARCIAL con anastomosis hepaticoyeyunal y gastroyeyunal (no se vieron LOES hepáticas).\n\nAP: CARCINOMA DE PÁNCREAS ENDOCRINO 3 cm, DE BAJO GRADO LOCALIZADO EN CABEZA PANCREÁTICA, 5/7 GANGLIOS AFECTOS. Cromogranina +, inmunorreacción para VIP moderadamente + pero negativa para el resto de hormonas (insulina, glucagón, serotonina, y pp). Índice proliferativo Ki 67 ≤ 1%. Necrosis hemorrágica de vesícula y esplenome\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}